Evidence map›Paper›PMID 36501171›Full record

ReviewNutrients2022

The Role of D-Serine and D-Aspartate in the Pathogenesis and Therapy of Treatment-Resistant Schizophrenia.

Regina F Nasyrova, Aiperi K Khasanova, Kuanysh S Altynbekov, Azat R Asadullin, Ekaterina A Markina, Arseny J Gayduk, German A Shipulin, Marina M Petrova, Natalia A Shnayder

Abstract readReview
In one paragraph

Review in Nutrients, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Regina F NasyrovaInstitute of Personalized Psychiatry and Neurology, Shared Core Facilities, V.M. Bekhterev National Medical Research Centre for Psychiatry and Neurology, 192019 Saint Petersburg, Russia.ORCID 0000-0003-1874-9434
Aiperi K KhasanovaInternational Centre for Education and Research in Neuropsychiatry, Samara State Medical University, 443016 Samara, Russia.ORCID 0000-0001-5391-0786
Kuanysh S AltynbekovRepublican Scientific and Practical Center of Mental Health, Almaty 050022, Kazakhstan.
Azat R AsadullinDepartment of Psychiatry and Addiction, The Bashkir State Medical University, 450008 Ufa, Russia.
Ekaterina A MarkinaDepartment of Psychiatry, Russian Medical Academy for Continual Professional Education, 125993 Moscow, Russia.
Arseny J GaydukDepartment of Psychiatry, Russian Medical Academy for Continual Professional Education, 125993 Moscow, Russia.
German A ShipulinCentre for Strategic Planning and Management of Biomedical Health Risks Management, 119121 Moscow, Russia.
Marina M PetrovaShared Core Facilities "Molecular and Cell Technologies", V.F. Voino-Yasenetsky Krasnoyarsk State Medical University, 660022 Krasnoyarsk, Russia.
Natalia A ShnayderInstitute of Personalized Psychiatry and Neurology, Shared Core Facilities, V.M. Bekhterev National Medical Research Centre for Psychiatry and Neurology, 192019 Saint Petersburg, Russia.ORCID 0000-0002-2840-837X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Schizophrenia (Sch) is a severe and widespread mental disorder. Antipsychotics (APs) of the first and new generations as the first-line treatment of Sch are not effective in about a third of cases and are also unable to treat negative symptoms and cognitive deficits of schizophrenics. This explains the search for new therapeutic strategies for a disease-modifying therapy for treatment-resistant Sch (TRS). Biological compounds are of great interest to researchers and clinicians, among which D-Serine (D-Ser) and D-Aspartate (D-Asp) are among the promising ones. The Sch glutamate theory suggests that neurotransmission dysfunction caused by glutamate

Indexed as

Aspartic AcidSchizophreniaD-Aspartic AcidGlutamic AcidHumansReceptors, N-Methyl-D-AspartateSchizophrenia, Treatment-ResistantSerineAspartic AcidD-Aspartic AcidGlutamic AcidReceptors, N-Methyl-D-AspartateSerineD-aspartatedisease-modifying therapyD-serinetreatment-resistant schizophrenia

Identifiers

PMID36501171
PMCPMC9736950

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.